11/23/20 9:06 AMNYSE : MRKMerck Animal Health Survey Reveals First-Time Dog Owners Need SupportMerck Animal Health, known as MSD Animal Health outside the US and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced a new survey about first-time dog owners and whether or not they were prepared for petRHEA-AIneutral
11/23/20 6:47 AMNYSE : MRKMerck Submits Applications for Licensure of V114, the Company's Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines AgencyMerck Submits Applications for Licensure of V114, the Company's Investigational 15-valent Pneumococcal Conjugate Vaccine, to the U.S. FDA and EMARHEA-AIneutral
11/17/20 1:25 PMNYSE : MRKMerck Announces First-Quarter 2021 DividendMerck Announces First-Quarter 2021 DividendRHEA-AIneutral
11/16/20 6:45 AMNYSE : MRKMerck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1RHEA-AIpositive
11/13/20 4:10 PMNYSE : MRKFDA Approves Merck's KEYTRUDA(R) (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS >=10)FDA Approves KEYTRUDA Plus Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS >=10)RHEA-AIneutral
11/10/20 6:45 AMNYSE : MRKKEYTRUDA(R) (pembrolizumab) Plus LENVIMA(R) (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Versus Sunitinib as First-Line Treatment for Patients...KEYTRUDA Plus LENVIMA Demonstrated Statistically Significant Improvement Versus Sunitinib as First-Line Treatment for Patients With Advanced RCCRHEA-AIpositive
11/05/20 6:52 AMNYSE : MRKPappas Capital Portfolio Company VelosBio to be Acquired by MerckPappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. ("VelosBio" or the "Company"), has entered into a definitive agreement to be acquired by aRHEA-AIvery positive
11/05/20 6:45 AMNYSE : MRKLYNPARZA(R) (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian CancerLYNPARZA (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian CancerRHEA-AIneutral
11/05/20 6:45 AMNYSE : MRKLYNPARZA(R) (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)LYNPARZA(R) (olaparib) Approved in the EU for Treatment of BRCA12-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)RHEA-AIneutral
